Thiol-based drugs have also been shown to decrease the binding of SARS-CoV-2 S-proteins to ACE2, inhibit viral entry and infection, and significantly decrease lung neutrophilic inflammation [70,71]. The gene discussed is PROS1; the disease is infection.